DDIT3 and diffuse large B-cell lymphoma: The results showed that R-CHOP-treated DLBCL patients in subtype I significantly exhibited shorter overall survival time than those in subtype II (p = 0.0041; Figure 2(a)), which were consistent with the results from the training set.